Dan Purvis, CEO of Velentium, will lead the new combined company. Photo courtesy of Veletium

A engineering firm based in Katy has made a strategic acquisition of a Magnolia, Texas-based company to start of the new year.

Velentium, which specializes in the design and manufacturing of medical devices announced that it has acquired Oasis Testing, a designer of automated test systems for the energy and manufacturing industries.

"Despite the immense challenges facing the business community in 2020, last year was a monumental year of growth for our firm, and we're pleased to start 2021 building upon our world-class team of technical experts," says Dan Purvis, CEO of Velentium, in a news release. "Oasis Testing has been a trusted partner for the last five years and shares in our commitment to solving clients' most complex challenges to change lives for a better world. We're incredibly excited to welcome them to the Velentium family and expand our business more deeply into energy and manufacturing."

The companies will operate under the Velentium name, and Demetri White, co-founder at Oasis Testing, will assume the role of senior program manager to focus on "growing the testing business, serving the oil and gas industry's need for high-pressure high-temperature test, as well as testing in the medical device sector," according to the release.

"We admire and share Velentium's approach to client service, company culture, and results-focused business strategy, and quickly recognized this would be an excellent fit for our team," says White in the. "From our years of partnership, we know that Oasis' expertise in servicing the energy and manufacturing sectors goes hand-in-hand with their ability to provide innovative and world class solutions. Together, we will leverage knowledge across industries to bring mechanical, electrical and software-based solutions that benefit our client base."

The new company will have expanded abilities and will be increasing its production space and headcount as it continues to place an emphasis on its testing and manufacturing capabilities. The added resources for automation and the combined team will lead to dramatic reductions in product test times and increased test system utilization.

Earlier this year, Velentium played a key role in mobilizing thousands of ventilators in the United States at a time when the pandemic and the uncertainty around it was surmounting around the country.

The company's long-time clients Ventec Life Systems, a manufacturer of ventilators based in Washington, said they could increase production of their much-needed ventilators five-fold if they only had the right resources and partners. Velentium first aimed to help the small factory double or triple their production, and later General Motors jumped in to help grow the initiative.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”